Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs Get Thin MD

Beluga Health
Graded #430

Lower grade

vs+10.900000000000006
Get Thin MD
Graded #179

Higher grade

The verdict

Get Thin MD takes it — 66.7/100 to 55.8/100.

Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGet Thin MD +5
45
50
Dose & formulationGet Thin MD +37
40
77
Clinical oversightGet Thin MD +14
76
90
Labs & monitoringBeluga Health +7
62
55
FulfillmentGet Thin MD +27
64
91
Contract termsBeluga Health +35
55
20
Beluga Health · left barGet Thin MD · right bar

The numbers

MetricBeluga HealthGet Thin MD
WeighScore55.8/10066.7/100
GradeCC
Scorecard rank#430#179
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Beluga Health

Graded #430 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
Get Thin MD

Graded #179 · C

Strengths

  • 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
  • Price-lock promise — same price every dose, no hidden fees
  • Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
  • Nationwide availability with async evaluation — no in-person visit
  • Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols

Where it loses points

  • Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
  • Pharmacy partners not named — no way to verify the compounding source or batch testing
  • Claims nationwide coverage but publishes no state list — confirm at intake
  • Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
  • Wide wellness funnel may steer you toward non-weight-loss protocols

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard